Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 504.98M P/E - EPS this Y 49.70% Ern Qtrly Grth -
Income -203.84M Forward P/E -2.34 EPS next Y 64.80% 50D Avg Chg 11.00%
Sales 2.26M PEG - EPS past 5Y - 200D Avg Chg -6.00%
Dividend N/A Price/Book 1.22 EPS next 5Y - 52W High Chg -94.00%
Recommedations 2.00 Quick Ratio 4.13 Shares Outstanding 119.44M 52W Low Chg 93.00%
Insider Own 18.17% ROA -53.56% Shares Float 45.59M Beta 0.61
Inst Own 80.41% ROE -96.56% Shares Shorted/Prior 7.40M/7.89M Price 4.64
Gross Margin 96.11% Profit Margin - Avg. Volume 660,960 Target Price 8.65
Oper. Margin -2,175.22% Earnings Date Nov 7 Volume 534,999 Change 0.87%
About Adagio Therapeutics, Inc.

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Adagio Therapeutics, Inc. News
11/15/24 Q3 2024 Invivyd Inc Earnings Call
11/15/24 Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...
11/14/24 Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
11/14/24 Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/14/24 Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
11/12/24 Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively
11/06/24 Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
11/06/24 Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
10/29/24 Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
10/29/24 Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
10/16/24 Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
10/01/24 Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
06:01 AM Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
09/14/24 We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate
09/12/24 Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
09/05/24 Invivyd to Participate in Upcoming Investor Conferences
09/04/24 Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
09/03/24 Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
08/27/24 Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
08/15/24 Q2 2024 Invivyd Inc Earnings Call
IVVD Chatroom

User Image navgun281 Posted - 14 hours ago

$IVVD buy more Monday

User Image Nik_CA Posted - 20 hours ago

$IVVD PTs by 5 analysts seems to be multiple X from the current SP. How soon do we see it run is anybody's guess?

User Image Nik_CA Posted - 20 hours ago

$IVVD Interesting numbers for the short shares availability. It appears someone knows something about P3 expected to be completed this month. See my previous post for the estimated study completion date.

User Image Nik_CA Posted - 20 hours ago

$IVVD Phase 3 of VYD222 (pemivibart) is estimated to end in Nov 2024. It remains to be seen if it is followed with a full FDA approval for pemivibart or would CT for VYD2311 will be expedited.

User Image Nik_CA Posted - 20 hours ago

$IVVD Study completion pf Phase 1 for VYD2311 is May 2025. The enrollment is bumped up from 30 to 40 participants. This is consistently in line with my expectations to see a strong movement during summer 2025.

User Image sintaka Posted - 1 day ago

$IVVD Can it be revived?

User Image Nik_CA Posted - 4 days ago

$IVVD This is no longer a risk. https://stocktwits.com/Nik_CA/message/593121799

User Image Nik_CA Posted - 4 days ago

$IVVD A must read for retail SHs to understand why Q3 revenue was lower than expected. Since the Ho Lab's inaccurate report is replaced by the validated pemivibart KP.3.1.1 neutralization data from Labcorp-Monogram Biosciences (Monogram) in September 2024, the PEMGARDA Fact Sheet continues to accurately reflect the neutralization activity of PEMGARDA (pemivibart) against KP.3.1.1. This implies that the revenue should pick up some steam. https://www.stocktitan.net/news/IVVD/invivyd-announces-new-england-journal-of-medicine-publishes-letter-i7qblavulu8q.html

User Image GakiYoui_Atsu Posted - 6 days ago

$WIMI Sick Bear trap at the open Bear falling for it every time $IVVD $QCOM

User Image SamGantVHee Posted - 1 week ago

$IVVD buy

User Image LionEagle Posted - 1 week ago

$PACB most bios are down due to the Trump trade. The entire market is coming back to its mean, which it should, from the election spike. I jumped back into PACB a few mins ago for a position trade. My other bios are down ($DDD $QSI $CERS $IVVD) and I have no intention on selling. By the way, someone said below that Cathie shorted this. She does not short and no smart fund manager would risk their entire portfolio over a $2 short gain with unlimited upside potential. With all the bios down, it's a good time to pick up more of your favs.

User Image ZACHSPIZZA Posted - 1 week ago

$IVVD Jesus

User Image d_risk Posted - 1 week ago

$IVVD - Invivyd Inc. Common Stock - 10Q - Updated Risk Factors Invivyd's risk factors now stress the impact of third-party lab data on product candidates, affecting regulatory approval and market acceptance, with recent FDA updates on PEMGARDA underscoring these concerns. #Risk @Invivyd https://d-risk.ai/IVVD/10-Q/2024-11-14

User Image VernonTasi Posted - 1 week ago

$IVVD What would be projected revenue for coming three quarters : Q4'24 - 20m Q1'25 - 40m Q2'25 - 80m Their current Loss per quarter is 60m and that is equivalent to 60x4 =240m. To get to profitability , revenue should be more than 60m per quarter and they expect that to happen H1 , which means they reach their revenue by H1. That is even a daunting target at this time. SP would be volatile though recover over time. There would be zero surprise. Hence, short term is bearish.

User Image Nik_CA Posted - 1 week ago

$IVVD Ivvd PR is inline with my projections “Targets near-term (1H 2025) profitability with existing cash and cash equivalents, anticipated growth of net product revenue, and various operational efficiency improvements”. Whether they can reach it is to be seen.😀

User Image Nik_CA Posted - 1 week ago

$IVVD Also, there’s another catalyst to watch for by EOY. “Next generation molecule VYD2311 first-in-human clinical trial dosing began in August 2024 with anticipated preliminary data readout late Q4 2024”.

User Image Nik_CA Posted - 1 week ago

$IVVD https://investors.invivyd.com/news-releases/news-release-details/invivyd-reports-third-quarter-2024-financial-results-and-recent/

User Image alexx013 Posted - 1 week ago

$IVVD added @ .90

User Image ZACHSPIZZA Posted - 1 week ago

$IVVD this turd. My second biggest unrealized loser thus far. Haven’t added again as floor is not confirmed. Waiting

User Image VXRT007 Posted - 1 week ago

$IVVD new PR today, not sure what that will do for the SP

User Image solidstate32 Posted - 2 weeks ago

$IVVD

User Image TWITLIEDETECTOR Posted - 3 weeks ago

$IVVD in case you are not following along. 13 key account manager openings and 1 strategic account manager director

User Image DonCorleone77 Posted - 3 weeks ago

$AZN $KYMR $VIR $ALNY $IVVD U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says U.S. drugmakers and biotechs rely on Chinese partners for manufacturing, research, and ingredients, but, with geopolitical tensions rising, companies are now looking for alternatives, Jared Hopkins and Clarence Leong of The Wall Street Journal reports. Pharmaceutical and biotechnology companies of all side are saying it's time to reduce China risk. Industry officials, however, note one consequence of this move may be slower drug rollouts and higher costs in the U.S. Companies making this move include AstraZeneca (AZN), Kymera Therapeutics (KYMR), Amicus Therapeutics (FOLD), Vir Biotechnology (VIR), Alnylam Pharmaceuticals (ALNY), Invivyd (IVVD).

User Image v5asi12345 Posted - 10/31/24

$IVVD Shorts are active but scared.. This is not going to zero.

User Image Serious_Hex_Est2020 Posted - 10/30/24

$IVVD $BA $WIMI

User Image Marianirl Posted - 10/30/24

$WIMI Investing is a lot like fishing, you can't guarantee that you will catch a fish after you cast your rod, so make sure you take every investment seriously $IVVD $BA

User Image GakiYoui_Atsu Posted - 10/30/24

Here's the list of stocks I bullish on 1. $META 2. $MU 3. $TSLA 4. $WIMI 5. $IVVD

User Image Marianirl Posted - 10/29/24

$WIMI messy market is good learning environment u get to learn both the bulls and bears $IVVD $AMC

User Image I_saw_the_kraken Posted - 10/29/24

$IVVD may someone give me some context about the company? Why did Morgan Stanley and H.C. Wainwright gave yesterday a price of $9,50 and $15 to this stock? Is this actually cooking something?

User Image alexx013 Posted - 10/29/24

$IVVD buying more here @ .91

Analyst Ratings
HC Wainwright & Co. Buy Sep 3, 24
HC Wainwright & Co. Buy Aug 30, 24
HC Wainwright & Co. Buy Aug 27, 24
HC Wainwright & Co. Buy May 24, 24
HC Wainwright & Co. Buy May 14, 24
Guggenheim Buy Apr 5, 24
Morgan Stanley Overweight Mar 26, 24
HC Wainwright & Co. Buy Mar 25, 24
HC Wainwright & Co. Buy Jan 18, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Elia Marc Director Director Aug 17 Buy 4.32 2,850,000 12,312,000 9,248,250 08/19/22
Royan Ajay Director Director Aug 12 Buy 17 1,997,000 33,949,000 11,241,580 08/12/21